References
- O'Sullivan P. J., Crowley J. G., Muldowney F. P. A case of acetazolamide induced (Diamox®) acidotic coma in polycystic renal disease. J. Irish. Med. Assoc 1967; 60: 382–84
- Lastnick G. Metabolic acidosis secondary to acetazolamide therapy - a possible hazardous side effect after prolonged use of acetazolamide in geriatric patients. A case report. Ariz. Med. 1975; 32: 9–21
- Siklos P., Henderson R. G. Severe acidosis from acetazolamide in a diabetic patient. Curr. Med. Res. Opin. 1979; 6: 284–86
- Maisey D. N., Brown R. D. Acetazolamide and symptomatic metabolic acidosis in mild renal failure. Br. Med. J. 1981; 283: 1527–28
- Gabay E. L. Metabolic acidosis from acetazolmide therapy. Arch. Ophthalmol. 1983; 101: 303–304
- Maren T. H. Chemistry of the renal reabsorption of bicarbonate. Can. J. Physiol. Pharmac 1974; 52: 1041–1050
- Maren T. H. To what extent does acetazolamide inhibit renal bicarbonate reabsorption. Scand. J. Clin. Lab. Invest. 1979; 39: 289–91
- Mathisen Ø., Holdaas H., Kiil F. Re-examination of the dose-response relationship for the renal effect of acetazolamide. Scand. J. Clin. Lab. Invest. 1979; 39: 297–301
- Lucci M. S., Pucacco L. R., Carter N. W., DuBose T. D. Evaluation of bicarbonate transport in rat distal tubule: effects of acid-base status. Am. J. Physiol. 1982; 243: F335–341
- Lucci M. S., Warnock D. G., Rector F. C. Carbonic anhydrase-dependent bicarbonate reabsorption in the rat proximal tubule. Am. J. Physiol. 1979; 236: F58–65
- Cain S. M. A ventilatory effect of carbonic anhydrase inhibition in man. Proc. Soc. Exp. Biol. Med. 1961; 106: 7–10
- White D. P., Zwillich C. W., Pickett C. K., Douglas N. J., Findley L. J., Weil J. V. Central sleep apnea-improvement with acetazolamide therapy. Arch. Intern. Med. 1982; 142: 1816–19
- Seldin D. W., Portwood R. M., Rector F. C., Cade R. Characteristics of renal bicarbonate reabsorption in man. J. Clin. Invest. 1959; 38: 1663–71
- Webster G. D., Huth E. J., Elkinton J. R., McCance R. A. The renal excretion of hydrogen ion in renal tubular acidosis. II. Quantitative response to the carbonic anhydrase inhibitor, acetazolamide. Am. J. Med. 1960; 29: 576–85
- Friedland B., Mallonee J., Anderson D. R. Short-term dose response characteristics of acetazolamide in man. Arch. Ophthalmol. 1977; 95: 1809–1812
- Aim A., Berggren L., Hartvig P., Roosdorp M. Monitoring acetazolamide treatment. Acta. Ophthalmol. 1982; 60: 24–34
- Maren T. H., Mayer E., Wadsworth B. C. Carbonic anhydrase inhibition. I. The Pharmacology of Diamox® 2-acetylamino-1,3,4-thiadiazole-5-sulfonamide. Bull. Johns. Hop. Hosp. 1954; 95: 199–243
- Lehmann B., Linnér E., Wistrand P. J. The pharmacokinetics of acetazolamide in relation to its use in the treatment of glaucoma and to its effects as an inhibitor of carbonic anhydrases. Adv. Bioscience 1969; 5: 197–217
- Maren T. H., Robinson B. The pharmacology of acetazolamide as related to cerebrospinal fluid and the treatment of hydrocephalus. Bull. Johns. Hop. Hosp. 1960; 106: 1–24
- Weiner I. M., Washington J. A., Mudge G. H. Studies on the renal excretion of salicylate in the dog. Bull. Johns. Hop. Hosp. 1959; 105: 284–297
- Wallace S. M., Shaw V. P., Riegelman S. GLC analysis of acetazolamide in blood, plasma, and saliva following oral administration to normal subjects. J. Pharm. Sci. 1977; 66: 527–530
- Arrigg C. A., Epstein D. L., Giovanoni R., Grant W. M. The influence of supplemental sodium acetate on carbonic anhydrase inhibitor-induced side effects. Arch. Ophthalmol. 1981; 99: 1969–72
- Posner J. B., Plum F. Spinal-fluid pH and neurologic symptoms in systemic acidosis. N. Engl. J. Med. 1967; 277: 605–13